Investigating the role of miglustat in the management of a patient with Tangier Disease
Tangier disease is a very rare inherited condition that stops the body from handling fats and cholesterol properly. Over time, fat builds up in nerves and organs, which can cause muscle weakness, numbness, and trouble walking. Currently, there is no cure, and standard low-fat diets often do not stop nerve damage. Doctors noticed that another patient improved when taking a medicine called miglustat. This clinical trial is designed for a single patient in England to test if miglustat really works for Tangier disease. Over two years, the patient will alternate between six months on the medication and six months off it. Researchers will measure nerve function, walking ability, hand strength, and daily quality of life. If the trial shows clear benefits, NHS England may consider funding the medicine for this patient in the long term.
Auf einen Blick
Worum geht es in dieser Studie?
Tangier disease is an extremely rare condition passed down through families. It affects how your body handles cholesterol and fats. In people with this condition, fatty substances build up in places they should not be, including the nerves, heart, and tonsils. When fat collects in the nerves, it can cause nerve damage. This often leads to clumsiness, loss of muscle strength in the hands and legs, and severe difficulty walking. Until now, doctors could only suggest a low-fat diet, which does not cure the illness or reliably prevent nerve damage.
A few years ago, doctors treated a woman who had nerve problems. They initially thought she had a different rare illness and gave her a medicine called miglustat. She improved significantly. Later, tests showed she actually had Tangier disease. When her doctors stopped the medicine, her symptoms worsened, but when they restarted it, she improved again. This unexpected discovery gave researchers hope that miglustat could protect nerves in people with Tangier disease.
Because Tangier disease is so uncommon, large clinical trials with hundreds of people are not possible. Instead, doctors are using an 'n-of-1' study design. This means the study is carefully tailored around one single person. NHS England has agreed to supply this expensive medicine for a patient in England, but they need solid evidence that it works before agreeing to fund it for long-term treatment.
Over two years, this patient will switch between taking miglustat and taking no study medicine in six-month blocks. By tracking how their nerves, strength, and mobility respond during both 'on' and 'off' periods, researchers hope to prove whether miglustat provides real, lasting relief from the nerve damage caused by Tangier disease.
Wichtige Erkenntnisse
- This trial is investigating whether the drug miglustat can treat nerve damage caused by Tangier disease.
- It is a single-patient study ('n-of-1' trial) lasting two years, and it is not recruiting other people.
- The participant switches between six months on the drug and six months off it to compare results.
- Regular checks include walking tests, grip strength tests, blood samples, and nerve tests.
- If the treatment works safely, NHS England may fund it for this patient in the future.
Wer könnte berechtigt sein?
This trial is what doctors call an 'n-of-1' study. That means it has been created to test a treatment in just one individual patient who has already been identified and chosen by the research team. Because of this, the study is not open for public recruitment.
To be suitable for this type of trial, a person must be an adult aged 18 or over with a confirmed diagnosis of Tangier disease. They must be able to understand the trial details, give informed consent, and agree to use reliable contraception to avoid fathering a child during the study, as the drug's effects on pregnancy are not fully known.
Anyone with severe kidney problems cannot take part, as this could make taking miglustat unsafe.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Diagnosed with Tangier disease
- Aged 18 years or older
- Already identified and contacted by the hospital study team
- No severe kidney disease
- Willing to use effective contraception throughout the study
Was beinhaltet die Teilnahme?
Taking part in this study lasts for about two years. The participant will go through four separate six-month periods, alternating between taking miglustat and taking no study drug, while continuing their normal health care.
Every six months, the participant will visit their regular specialist clinic for a physical check-up, routine blood tests, and urine tests. Extra blood samples will also be taken to study how the body responds to the drug. Every two months, they will see a physiotherapist for hand tests, such as putting pegs into a board and squeezing a handgrip device to test muscle strength.
Twice a year, the participant will have walking tests to measure their speed and endurance over six minutes, as well as a nerve conduction test, which uses tiny electrical pulses on the skin to check nerve health. Finally, they will fill out a one-week food and drink diary every six months to track their diet.
Potenzielle Risiken und Vorteile
Standorte (1)
- University Hospitals Birmingham NHS Foundation TrustNur StadtBirmingham, England
Häufige Fragen
Can I sign up for this clinical trial?
No. This trial is designed for only one specific patient who has already been selected by the study team. It is not currently recruiting other participants.
What is an 'n-of-1' clinical trial?
An 'n-of-1' trial is a study focused entirely on a single person. It is often used for extremely rare conditions where there are not enough patients to run a standard group study.
What does the medicine miglustat do?
Miglustat is an existing medicine used for other rare metabolic conditions. Doctors believe it may help stop harmful fatty substances from building up and damaging nerves in Tangier disease.
Why does the patient stop taking the medicine every six months?
Switching between taking the medicine and not taking it allows doctors to compare nerve function during both stages. This helps prove whether any improvements are truly caused by the drug.
What happens if the drug works well?
If the study shows clear evidence that miglustat helps protect the patient's nerves and improves daily life, NHS England may agree to fund the medicine for them as a long-term treatment.
Wie Sie mehr erfahren können
Tarekegn Hiwot
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.